HAE Stock Recent News

BOSTON , July 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, August 7, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 7, 2025.

FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy, providing a major competitive advantage over injectable options. EKTERLY's convenience and rapid symptom relief position it for strong market adoption, with a $4 billion HAE market opportunity and potential to shift on-demand market share. Global expansion is underway, with seven regulatory submissions, and if approved for these territories, it could increase the amount of revenues that are to be generated.

Live Updates Live Coverage Has Ended So Close and Yet so Far 4:09 pm by Gerelyn Terzo The S&P 500 and Nasdaq Composite indices both crossed over into record territory during today’s trading session but they came off those lofty levels by the market closing. The Nasdaq Composite still closed up about 1% to 20,167.91 while the S&P 500 index finished the day 0.80% higher at 6,141.02. Big Tech Downgrade 12:55 pm by Gerelyn Terzo While Tesla stock received a ringing endorsement from Wall Street analysts today, Apple (Nasdaq: AAPL) is seeing the other side of the spectrum. JPMorgan analysts lowered their price target on the iPhone maker to $230 from $240, keeping their “overweight” rating on the stock. The analysts are worried about demand for the iPhone 17. Apple shares are lower by 0.79% today. The Nasdaq Composite is now up 0.70%. Benchmark Bullish on TSLA 11:01 am by Gerelyn Terzo Wall Street research firm Benchmark is bullish on EV leader Tesla (Nasdaq: TSLA).

ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association's 2025 National Summit to be held from July 10-13, 2025, in Baltimore, Maryland.

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has granted Pendopharm, a division of Pharmascience Inc., the exclusive rights to manage the regulatory approval process and commercialization of sebetralstat in Canada. Sebetralstat is an investigational, oral on-demand treatment for hereditary angioedema (HAE). “We look forward to collaborating with Pendopharm,.

ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a least squares mean of 89.2 percent, compared to placebo ANDEMBRY approval expands CSL's HAE franchise and underscores the company's legacy of delivering transformational innovations to the HAE community for over four decades KING OF PRUSSIA, Pa. , June 16, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the U.S. Food and Drug Administration (FDA) approved ANDEMBRY® (garadacimab-gxii), the only treatment targeting factor XIIa for prophylactic use to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of new data at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom that underscores the critical role of effective on-demand (OD) treatment for HAE attacks among patients receiving long-term prophylaxis (LTP). Sebetralstat for Treatment of HAE Attacks in Patients Receiving Berotralstat, Lanadelumab, or C1 Inhi.

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life

BOSTON , May 30, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:40 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://event.webcasts.com/starthere.jsp?ei=1721260&tp_key=3096fdc651&tp_special=8 A replay of the recorded webcast will become accessible 12 hours after the event and will be available for 90 days on Haemonetics' Investor Relations website.